

Drospirenone Containing Oral Contraceptives Drug Use Criteria

Created: October 2014

Reviewed: September 2015, April 2019

Includes:

Yaz ®	<i>Ethinyl Estradiol and Drospirenone</i>
Yasmin ®	<i>Ethinyl Estradiol and Drospirenone</i>
Zarah ®	<i>Ethinyl Estradiol and Drospirenone</i>
Vestura ®	<i>Ethinyl Estradiol and Drospirenone</i>
Syeda ®	<i>Ethinyl Estradiol and Drospirenone</i>
Ocella ®	<i>Ethinyl Estradiol and Drospirenone</i>
Nikki ®	<i>Ethinyl Estradiol and Drospirenone</i>
Loryna ®	<i>Ethinyl Estradiol and Drospirenone</i>
Gianvi ®	<i>Ethinyl Estradiol and Drospirenone</i>
Zumandimine ®	<i>Ethinyl Estradiol and Drospirenone</i>
Jasmiel ®	<i>Ethinyl Estradiol and Drospirenone</i>

**or any other brand or generic formulation of oral contraceptive containing drospirenone.

Guideline for Use:

1. Is the patient being treated for a funded condition by Oregon Health Plan?
 - a. If yes, go to 2
 - b. If no, deny as Below the Funded Line for Oregon Health Plan.
2. Does the patient have Polycystic Ovary Syndrome (PCOS) supported in the chart notes submitted for review?
 - a. If yes, approve for 12 fills.
 - b. If no, go to 3
3. Does the patient have Premenstrual Dysphoric Disorder (PMDD) supported in the chart notes submitted for review?
 - a. If yes, approve for 12 fills.
 - b. If no, deny as not meeting criteria. Please use formulary alternative.

Rationale:

Drospirenone containing oral contraceptives have been associated with an increased risk of thromboembolic events; therefore, in order to ensure the safest and most cost-effective oral contraceptive preparations are utilized for Advanced Health members, the above drug use criteria was developed. Acne must meet Guideline Note 132: Acne Conglobata and Acne Fulminans or Guideline Note 65: Severe Cystic Acne of the Prioritized List of Health Services to be considered a covered comorbid condition.

Approved by DOCS/WOAH Pharmacy and Therapeutics Committee on 10/27/2014

Approved by Advanced Health Pharmacy and Therapeutics Committee on 4/22/19, 1/22/20, 1/7/21

FDA Approved Indications: Indicated for the prevention of pregnancy, treatment of premenstrual dysphoric disorder (PMDD), and treatment of acne.

References:

Lexicomp. Ethinyl Estradiol and Drospirenone: Drug Information. Last updated 12/7/21.
Health Evidence Review Commission Prioritized List of Health Services. Guideline Note 132: Acne Conglobata and Acne Fulminans and Guideline Note 65: Severe Cystic Acne. October 1, 2021 Prioritized List.

Approved by DOCS/WOAH Pharmacy and Therapeutics Committee on 10/27/2014

Approved by Advanced Health Pharmacy and Therapeutics Committee on 4/22/19, 1/22/20, 1/7/21